<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The binding of vascular endothelial growth factor (VEGF) to its receptors stimulates <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e>; therefore, modulation of VEGF would be a viable approach for antiangiogenic therapy </plain></SENT>
<SENT sid="1" pm="."><plain>We constructed a series of soluble decoy receptors containing different VEGF receptor 1 (FLT1) and VEGF receptor 2 (KDR) extracellular domains fused with the Fc region of human immunoglobulin (Ig) and evaluated their antiangiogenic effects and antitumor effects </plain></SENT>
<SENT sid="2" pm="."><plain>Results of in vitro binding and cell proliferation assays revealed that decoy receptor FP3 had the highest affinity to VEGF-A and -B </plain></SENT>
<SENT sid="3" pm="."><plain>Compared with bevacizumab, FP3 more effectively inhibited human umbilical vein endothelial cell (HUVEC) migration and vessel sprouting from rat aortic rings </plain></SENT>
<SENT sid="4" pm="."><plain>FP3 significantly reduced phosphorylation of AKT and ERK1/2, critical proteins in the VEGF-mediated survival pathway in endothelial cells </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, FP3 inhibited <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in human <z:hpo ids='HP_0001402'>hepatocellular carcinoma</z:hpo> (HepG2), <z:hpo ids='HP_0003002'>breast cancer</z:hpo> (MCF-7), and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (LoVo) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> models, and reduced microvessel density in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues </plain></SENT>
<SENT sid="6" pm="."><plain>The FP3-mediated inhibition of <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> was significantly higher than that of bevacizumab at the same dose </plain></SENT>
<SENT sid="7" pm="."><plain>FP3 also demonstrated synergistic antitumor effects when combined with <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU) </plain></SENT>
<SENT sid="8" pm="."><plain>Taken together, FP3 shows a high affinity for VEGF and produced antiangiogenic effects, suggesting its potential for treating <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>-related diseases such as <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>